AE-C Exam Prep — 11 Week Study Plan

Week 1 — Part I: The Asthma Condition

Difficulty: Heavy

What it covers: Part I builds the disease-mechanism foundation every other Part assumes. You will learn the four hallmarks of asthma pathophysiology (inflammation, bronchoconstriction, airway hyperresponsiveness, and remodeling), the early-phase versus late-phase allergic response and the cells and mediators that drive each, the difference between severity, control, impairment, and risk and how each construct gets used in patient assessment, asthma phenotypes (allergic, eosinophilic, exercise-induced, occupational, AERD), how presentation and evaluation shift across infants, children, adolescents, adults, and older adults, the medications that exacerbate asthma (beta-blockers, NSAIDs/aspirin, sulfite-containing agents), and how to differentiate vocal cord dysfunction from asthma.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System

☐ Lock in the four hallmarks of asthma pathophysiology before anything else. Inflammation is persistent infiltration of the airway wall by eosinophils, mast cells, and Th2 lymphocytes. Bronchoconstriction is reversible smooth-muscle narrowing. Airway hyperresponsiveness (AHR) is an exaggerated bronchoconstrictor response to stimuli that would not affect a normal airway. Airway remodeling is long-term structural change — subepithelial fibrosis, smooth muscle hypertrophy, mucus gland hyperplasia, angiogenesis — that may render obstruction only partially reversible. Every "why does this happen" question on the AE-C traces back to one of these four.

☐ Master the early-phase versus late-phase allergic response. Early phase begins within minutes of allergen exposure, peaks at roughly 15–30 minutes, resolves within 1–2 hours, and is bronchospasm-dominant — driven by IgE-mediated mast cell degranulation. Late phase emerges 4–12 hours after exposure, is driven by eosinophil and lymphocyte infiltration, and produces edema, mucus, and prolonged hyperresponsiveness. The exam tests this distinction by varying the timing in the stem.

☐ Build a clean side-by-side for severity, control, impairment, and risk. Severity is the intrinsic intensity of the disease before long-term controller therapy is started — classified as intermittent, mild persistent, moderate persistent, or severe persistent. Control is how well asthma is being managed on the current regimen — well controlled, not well controlled, or very poorly controlled. Impairment is the present-tense burden (daytime symptoms, nighttime awakenings, reliever use, activity limitation, lung function). Risk is the likelihood of future adverse events (exacerbations, lung-function loss, treatment side effects). Severity guides starting therapy; control guides ongoing therapy.

☐ Anchor the medications that exacerbate asthma. Non-selective beta-blockers can provoke bronchoconstriction by blocking beta-2 receptors (cardioselective agents are safer but not risk-free). NSAIDs and aspirin can trigger reactions in patients with AERD — the syndrome of adult-onset asthma, chronic rhinosinusitis with nasal polyps, and respiratory reactions to COX-1 inhibitors. Sulfite-containing agents (some wines, dried fruits, certain medications) can provoke symptoms in sensitive patients. Counseling patients on these is a routine AE-C duty.

☐ Master vocal cord dysfunction (VCD) versus asthma. VCD is paradoxical adduction of the vocal cords during inspiration, producing stridor and dyspnea that mimic asthma but do NOT respond to bronchodilators. The exam tests this with a "treatment-refractory asthma" scenario where the right next step is a referral for laryngoscopy, not another step-up. Recognizing what is NOT asthma is as testable as recognizing what is.

☐ Complete the Practice Questions for Part I in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = The Asthma Condition. Main branches: Four Hallmarks of Asthma Pathophysiology (inflammation, bronchoconstriction, AHR, remodeling) → Early-Phase vs. Late-Phase Allergic Response → Severity vs. Control → Impairment vs. Risk → Asthma Phenotypes (allergic, eosinophilic, EIB, occupational, AERD) → Age-Group Variations → Medications That Exacerbate Asthma → Comorbidities → Vocal Cord Dysfunction.

Comparison Charts:

☐ Chart 1 — Early-Phase vs. Late-Phase Allergic Response: Onset timing, peak timing, duration, dominant cells (mast cells vs. eosinophils/lymphocytes), dominant mechanism (bronchospasm vs. inflammation), and the clinical implication for short-acting versus controller therapy.

☐ Chart 2 — Severity vs. Control vs. Impairment vs. Risk: Definition, when each is assessed, what guides each measurement, and which therapy decision each one drives.

☐ Chart 3 — Asthma vs. Vocal Cord Dysfunction vs. AERD: Underlying mechanism, hallmark symptom (wheeze vs. stridor vs. polyps + reactions), response to bronchodilator, diagnostic test of choice, and the management pivot point that distinguishes each.

Cornell Notes:

☐ Page 1 — Cue questions: What are the four hallmarks of asthma pathophysiology, and which one explains why severe long-standing asthma is only partially reversible? What is the difference between the early-phase and late-phase allergic response in timing, mediators, and dominant mechanism?

☐ Page 2 — Cue questions: What is the difference between severity, control, impairment, and risk, and which is assessed before starting controller therapy versus at every follow-up visit? Which three medication categories most commonly exacerbate asthma, and what counseling does each require?

Week 2 — Part II: Assessment — History and Physical Signs

Difficulty: Heavy

What it covers: Part II turns the disease framework into a structured patient encounter. You will learn the components of a comprehensive asthma history (symptom pattern, triggers, response to therapy, exacerbation history, psychosocial factors), the high-risk markers that predict exacerbation, hospitalization, and asthma-related death, criteria for specialist referral, the auscultation findings that distinguish asthma from upper-airway obstruction and parenchymal disease, the silent chest as a sign of life-threatening obstruction (not improvement), pulsus paradoxus, accessory muscle use, retractions, the tripod position, and how to triage a symptomatic patient between home rescue therapy, urgent office visit, ED, or 911.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the silent chest before anything else in this Part. The silent chest is diminished or absent breath sounds during a severe exacerbation — airflow has dropped so low that wheeze can no longer be generated. It is a respiratory emergency, not an improvement, and the AE-C tests it directly because the wrong answer is "the patient is doing better." A silent chest in a patient with worsening distress, accessory muscle use, or altered mentation is a 911-level finding.

☐ Master the wheeze-versus-stridor-versus-rhonchi-versus-crackles distinction. Wheeze is continuous, musical, high-pitched, predominantly EXPIRATORY, generated by airflow through narrowed lower airways — the classic asthma sound. Stridor is continuous, harsh, high-pitched, predominantly INSPIRATORY, originating from upper-airway (laryngeal/tracheal) obstruction — NOT asthma. Rhonchi are continuous, low-pitched, snoring or gurgling sounds from secretions in larger airways. Crackles (rales) are discontinuous, popping sounds from alveolar opening or fluid — pneumonia, edema, fibrosis — NOT typical asthma. The exam will give you a sound and ask whether it points toward asthma or away from it.

☐ Build a clean reference for high-risk asthma markers. Prior intubation, prior ICU admission, two or more hospitalizations or three or more ED visits in the past year, two or more SABA canisters per month, recent or chronic systemic corticosteroid use, low socioeconomic resources, illicit drug use, major psychosocial issues, and poor symptom perception are the markers that predict severe future events including death. A patient with any of these warrants closer follow-up and a more aggressive action plan, regardless of how they look in clinic today.

☐ Anchor the triage decision. A symptomatic patient is managed at home with the action plan if symptoms are mild and respond to a reliever; brought to the office or urgent care for moderate symptoms with partial response; sent to the ED for severe symptoms, no response to reliever, or any high-risk feature; and 911 is activated for impending respiratory failure (silent chest, altered mentation, cyanosis, exhaustion). The AE-C tests this decision tree by varying which findings are present in the stem.

☐ Master pulsus paradoxus and the external signs of severe distress. Pulsus paradoxus is an exaggerated drop in systolic blood pressure (greater than 10 mmHg, severe at greater than 25 mmHg) during inspiration in a severe attack, reflecting marked intrathoracic pressure swings. Accessory muscle use (sternocleidomastoid, scalene, intercostals), retractions (intercostal, suprasternal, supraclavicular, subcostal — particularly important in pediatrics), and the tripod position (patient leaning forward with arms braced) are external signs that the patient is recruiting every available muscle to move air. None of these belongs in mild disease.

☐ Complete the Practice Questions for Part II in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = History and Physical Signs. Main branches: Comprehensive Asthma History → High-Risk Markers → Specialist Referral Criteria → Auscultation (wheeze, stridor, rhonchi, crackles, silent chest) → Pulsus Paradoxus → Accessory Muscle Use & Retractions → Tripod Position → Symptom Perceiver vs. Poor Perceiver → Triage Decision (home, office, ED, 911) → Comorbidities Detected on Exam.

Comparison Charts:

☐ Chart 1 — Wheeze vs. Stridor vs. Rhonchi vs. Crackles vs. Silent Chest: Pitch, continuity, respiratory phase, anatomic origin, what it points toward, and the exam-stem trap built into each.

☐ Chart 2 — Mild vs. Moderate vs. Severe vs. Life-Threatening Exacerbation: Symptoms, mental status, breath sounds, accessory muscle use, peak flow as % of personal best, oxygen saturation, and the corresponding triage destination.

☐ Chart 3 — Lower-Risk vs. High-Risk Asthma Patient: History markers (prior intubation, hospitalizations, ED visits, SABA canister use, steroid use, psychosocial), implication for follow-up cadence, action plan aggressiveness, and threshold for specialist referral.

Cornell Notes:

☐ Page 1 — Cue questions: What auscultation finding most strongly suggests asthma rather than upper-airway obstruction or parenchymal disease, and how do you interpret a silent chest in a distressed patient? What are five high-risk markers that predict severe future asthma events including death?

☐ Page 2 — Cue questions: What is pulsus paradoxus, and at what threshold does it indicate severe airflow limitation? How do you triage a symptomatic asthma patient between home rescue therapy, urgent office visit, ED, and 911 — and which findings push the decision to each level?

Week 3 — Part III: Assessment — Objective Measures

Difficulty: Heavy

What it covers: Part III is the numbers Part — the objective tests that confirm asthma, grade severity, and document response. You will master spirometry (FEV1, FVC, FEV1/FVC, lower limit of normal), the bronchodilator reversibility criteria (12% AND 200 mL rule), fractional exhaled nitric oxide (FeNO) thresholds, pulse oximetry action levels, the methacholine challenge with PC20 interpretation, exercise challenge with the FEV1 fall threshold, skin prick testing versus specific IgE blood testing, peak flow technique with personal best establishment, and the ATS/ERS acceptability and repeatability criteria that validate every spirometry maneuver you read.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the bronchodilator reversibility rule before anything else in this Part. A positive test in adults requires BOTH a 12% increase from baseline AND a 200 mL absolute increase in FEV1 (or FVC) after a short-acting bronchodilator. Either one alone is not enough — the AE-C tests this by giving a stem with a 14% increase but only 150 mL, or a 250 mL increase that is only 8%, and the right answer is "not reversible by criteria." Get this rule cold before anything else.

☐ Master the FEV1/FVC ratio and the lower limit of normal (LLN). An FEV1/FVC ratio below the LLN (typically the 5th percentile of a healthy reference population, adjusted for age, sex, height, and ethnicity) defines obstruction. The traditional fixed cutoff of 0.70 still appears on the exam but is increasingly replaced by LLN, which corrects for the natural decline of the ratio with age. Use LLN when reference equations are available; the fixed 0.70 is a fallback.

☐ Build a clean reference for FeNO interpretation. FeNO is a noninvasive marker of eosinophilic (Type-2) airway inflammation, measured in parts per billion (ppb). Adult thresholds: low less than 25 ppb, intermediate 25–50 ppb, high greater than 50 ppb. Pediatric thresholds: low less than 20 ppb, intermediate 20–35 ppb, high greater than 35 ppb. High FeNO supports a Type-2 phenotype that is likely to respond to inhaled corticosteroids and to anti-IgE, anti-IL-5, anti-IL-4Rα, or anti-TSLP biologics. Low FeNO does not exclude asthma but suggests a non-Type-2 phenotype.

☐ Anchor the methacholine challenge and the PC20. The methacholine challenge is a bronchoprovocation test used when spirometry is normal but asthma is still suspected — the patient inhales increasing doses of methacholine until FEV1 drops 20% from baseline. The PC20 is the provocative concentration that produces that 20% drop. A PC20 of 4 mg/mL or less strongly supports asthma, and a PC20 of greater than 16 mg/mL effectively rules out airway hyperresponsiveness. The exercise challenge uses the same logic — a fall in FEV1 of 10% or more from baseline after a controlled exercise protocol is positive for exercise-induced bronchoconstriction.

☐ Master peak flow technique and personal best. The personal best peak flow is the patient's highest PEF over a 2- to 3-week period of well-controlled asthma — used as the reference for action plan zones rather than predicted values, because predicted values miss patient-specific variation. Three forced exhalations are taken and the highest is recorded; technique errors include incomplete inhalation, leak around the mouthpiece, and tongue blocking the device. A drop to less than 50% of personal best signals a severe exacerbation.

☐ Complete the Practice Questions for Part III in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Objective Measures. Main branches: Spirometry (FEV1, FVC, FEV1/FVC, LLN) → Bronchodilator Reversibility (12% AND 200 mL) → FeNO Thresholds (adult vs. pediatric) → Pulse Oximetry Action Levels → Methacholine Challenge & PC20 → Exercise Challenge & 10% FEV1 Fall → Skin Prick Test vs. Specific IgE → Peak Flow & Personal Best → ATS/ERS Acceptability & Repeatability.

Comparison Charts:

☐ Chart 1 — Spirometry vs. Peak Flow vs. FeNO: What each measures, sensitivity to obstruction, role in diagnosis vs. monitoring, technique demands, and the clinical scenario that calls for each.

☐ Chart 2 — Methacholine Challenge vs. Exercise Challenge: Provocation method, primary endpoint (PC20 vs. % FEV1 fall), positive threshold, when each is chosen, and patient preparation requirements.

☐ Chart 3 — Skin Prick Test vs. Specific IgE Blood Test: How each is performed, time to result, role of medication interference (especially antihistamines), patient factors that drive choice (skin disease, dermatographism, anaphylaxis history), and how the result is reported.

Cornell Notes:

☐ Page 1 — Cue questions: What are the two criteria that must BOTH be met for a positive bronchodilator reversibility test in adults, and what is the most common exam trap built around this rule? What FEV1/FVC ratio defines obstruction, and how does the lower limit of normal differ from the fixed 0.70 cutoff?

☐ Page 2 — Cue questions: What are the adult and pediatric FeNO thresholds for low, intermediate, and high airway inflammation, and what does a high FeNO predict about treatment response? What is the PC20 threshold on methacholine challenge that strongly supports asthma versus the threshold that effectively rules out airway hyperresponsiveness?

Week 4 — Part IV: Assessment — Educational Needs

Difficulty: Moderate

What it covers: Part IV moves from clinical data to the patient. You will learn how to identify financial, cultural, and attitudinal barriers to adherence and pair each with a tailored response, recognize the four VARK learning preferences (visual, auditory, reading/writing, kinesthetic) and adapt teaching accordingly, screen for limited health literacy and apply plain-language and teach-back routinely, apply the LEARN cultural-competence framework, distinguish cultural competence from cultural humility, use open-ended versus closed-ended questions purposefully, and conduct a multidimensional assessment that integrates clinical, behavioral, social, environmental, and psychological domains.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in adherence vs. compliance vs. concordance before anything else in this Part. Adherence is the extent to which the patient's actions match agreed-upon recommendations and is the preferred term because it emphasizes patient agency. Compliance is older language that implies the patient simply follows clinician orders and is now generally avoided because it frames the relationship as one-directional. Concordance is the negotiated model in which clinician and patient build a shared plan based on the patient's beliefs, preferences, and capabilities. The AE-C exam uses this language carefully — pay attention to which word is in the stem.

☐ Master the teach-back method. Teach-back is asking the patient to explain in their own words what they have just been taught — the gold-standard technique for confirming understanding. The phrasing matters: "I want to make sure I explained this clearly — can you walk me through how you'll use your inhaler at home?" places responsibility on the educator, NOT the patient. "Do you understand?" is not teach-back and does not confirm anything. The exam tests both the technique and the phrasing.

☐ Build a clean reference for the LEARN model. LEARN is a five-step cultural-competence framework: Listen with sympathy and understanding to the patient's perception of the problem, Explain your perceptions of the problem, Acknowledge and discuss the differences and similarities, Recommend treatment, Negotiate agreement. The pattern is structured to bridge the clinician's biomedical model and the patient's explanatory model — without that bridge, recommendations will be heard but not adopted.

☐ Anchor cultural competence vs. cultural humility. Cultural competence is the set of knowledge, skills, and behaviors that enable effective care across cultures — language, beliefs about illness, family roles, health practices. Cultural humility is the ongoing, lifelong commitment to self-reflection, openness, and recognizing power differentials — it COMPLEMENTS, rather than replaces, cultural competence. Implicit bias — unconscious attitudes or stereotypes that influence understanding, actions, and decisions — affects every clinician and warrants active self-examination. The exam tests the distinction by giving a scenario where one is sufficient and the other is not.

☐ Master open-ended vs. closed-ended questioning. Open-ended questions invite a narrative or descriptive answer ("Tell me about…", "What is it like when…") and are the right tool for exploring beliefs, concerns, prior experience, and self-management knowledge. Closed-ended questions have a yes/no or short factual answer and are useful for confirming specifics but limited for exploration. The exam tests this with a scenario where the patient is reluctant to share — the right answer is to switch FROM closed TO open, not the reverse.

☐ Complete the Practice Questions for Part IV in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Educational Needs. Main branches: Adherence vs. Compliance vs. Concordance → Barriers (financial, cultural, attitudinal, steroid phobia) → VARK Learning Styles → Health Literacy & Numeracy → Teach-Back Method → Plain Language → LEARN Model → Cultural Competence vs. Cultural Humility → Implicit Bias → Open-Ended vs. Closed-Ended Questioning → Health Belief Model → Stages of Change → Motivational Interviewing → Multidimensional Assessment → Social Determinants of Health.

Comparison Charts:

☐ Chart 1 — Adherence vs. Compliance vs. Concordance: Definition, what each implies about clinician–patient power, when each term is appropriate, and the framing the AE-C exam treats as preferred.

☐ Chart 2 — Cultural Competence vs. Cultural Humility: Definition, time horizon (acquired skill vs. lifelong commitment), focus (knowledge vs. self-reflection), relationship (replacement vs. complement), and a scenario where each one alone falls short.

☐ Chart 3 — Open-Ended vs. Closed-Ended Questions: Form, type of information elicited, when each is the right tool, the most common misuse, and the corrective phrasing for a clinician who is closing every question.

Cornell Notes:

☐ Page 1 — Cue questions: What is the difference between adherence, compliance, and concordance, and which framing does the AE-C exam treat as preferred? What is the teach-back method, and what is the difference between a teach-back question and a closed "do you understand?" question? ☐ Page 2 — Cue questions: What are the five steps of the LEARN model, and why does a strict biomedical recommendation often fail without the explanatory-model step? What is the difference between cultural competence and cultural humility, and how does implicit bias fit into both?

Week 5 — Part V: Management — Medications

Difficulty: Heavy — High Yield

What it covers: Part V is the highest-density content Part in the book and one of the most heavily tested sections of the AE-C. You will learn the stepwise asthma therapy approach across age groups (adults/adolescents, school-age children, preschoolers), every controller medication class by mechanism and clinical role, the SMART/MART therapy approach using ICS-formoterol as both daily controller and reliever, SABA overuse red flags, the absolute prohibition on LABA monotherapy, the LTRA (montelukast) neuropsychiatric boxed warning, ICS local and systemic side effects and how to prevent them, systemic corticosteroid burst dosing for exacerbations across age groups, and how to differentiate the six biologics — omalizumab, mepolizumab, benralizumab, dupilumab, reslizumab, and tezepelumab — by mechanism, biomarker, and clinical scenario.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the LABA monotherapy prohibition before anything else in this Part. A long-acting beta agonist (LABA) is NEVER used as monotherapy in asthma — the increased mortality risk demonstrated in trials drives this absolute rule. LABAs must always be paired with an inhaled corticosteroid (ICS), either as a fixed-combination inhaler or, in SMART/MART therapy, as ICS-formoterol used for both daily control and reliever. The exam tests this by giving a stem where the wrong answer is "add a LABA-only inhaler" — the right answer is always "ICS + LABA combination."

☐ Master SMART therapy. SMART (Single Maintenance And Reliever Therapy) is the use of an ICS-formoterol combination as BOTH the daily controller AND the reliever. MART is the international term for the same approach. Only formoterol-based combinations are approved for SMART because of formoterol's rapid onset (similar to albuterol) — salmeterol-based combinations are NOT approved for reliever use. The advantage is that every reliever puff also delivers an anti-inflammatory dose, which addresses the underlying inflammation that drove the symptom in the first place.

☐ Build a clean reference for SABA overuse red flags. Use of more than two SABA canisters per month — or filling a SABA prescription more often than expected — signals poor control and elevated risk of severe exacerbation and death. The right response is NOT another SABA; it is reassessing technique, adherence, triggers, and stepping up controller therapy. The AE-C tests this by giving a patient using a rescue inhaler "almost every day" and asking what to do — the answer is escalate the controller, not refill the rescue.

☐ Anchor the LTRA (montelukast) neuropsychiatric boxed warning. Montelukast carries an FDA boxed warning for neuropsychiatric events including agitation, depression, sleep disturbances, and suicidal thoughts and behavior. Counseling patients and families about this warning is required before initiating therapy and at follow-up visits, and the appearance of any neuropsychiatric symptoms is a reason to reassess the risk-benefit balance. The exam tests this directly with a scenario where a patient on montelukast presents with new mood changes — the right answer is to discuss discontinuation with the prescriber.

☐ Master the six biologics by biomarker and target. Omalizumab (Xolair) is anti-IgE, indicated for moderate-to-severe persistent allergic asthma with documented sensitization, dosed by weight and serum IgE. Mepolizumab (Nucala) is anti-IL-5 for severe eosinophilic asthma. Benralizumab (Fasenra) is anti-IL-5 receptor alpha, depleting eosinophils via antibody-dependent cell-mediated cytotoxicity. Reslizumab (Cinqair) is anti-IL-5 delivered as a weight-based IV infusion. Dupilumab (Dupixent) is anti-IL-4 receptor alpha, blocking IL-4 and IL-13 — effective in Type-2 high asthma and also in atopic dermatitis and chronic rhinosinusitis with nasal polyps. Tezepelumab (Tezspire) is anti-TSLP, acting upstream in the inflammatory cascade and effective across phenotypes regardless of eosinophil count. The biomarker that selects each is the testable hinge.

☐ Master systemic corticosteroid burst dosing. A steroid burst is a short course of oral corticosteroid (typically prednisone) for an acute exacerbation — commonly 5–7 days in adults and 3–5 days in children. No taper is required if the course is short and the patient is on an inhaled corticosteroid baseline. Repeated bursts (more than two per year) are themselves a marker of poor control and a trigger to step up controller therapy.

☐ Complete the Practice Questions for Part V in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Medications. Main branches: Stepwise Therapy (adults/adolescents, school-age, preschool) → Controllers (ICS, ICS-LABA, LTRA, LAMA add-on) → Relievers (SABA, ICS-formoterol) → SMART/MART Therapy → SABA Overuse Red Flags → LABA Monotherapy Prohibition → LTRA Neuropsychiatric Boxed Warning → ICS Side Effects (oral thrush, dysphonia, growth velocity, systemic) → Steroid Burst Dosing → Six Biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, tezepelumab) → Phenotype-Based Therapy.

Comparison Charts:

☐ Chart 1 — Controller Medication Classes: ICS, ICS-LABA, LTRA, LAMA add-on — mechanism, role in stepwise therapy, age range approved, key side effect, and the patient profile that selects each.

☐ Chart 2 — SABA Reliever vs. SMART Reliever (ICS-Formoterol): Mechanism, anti-inflammatory effect (no vs. yes), use as daily controller (no vs. yes), populations approved, and the exam-stem signal that the right answer is SMART.

☐ Chart 3 — Six Biologics for Severe Asthma: Target (IgE, IL-5, IL-5Rα, IL-4Rα, TSLP), biomarker that selects each (serum IgE, blood eosinophils, FeNO, atopic comorbidities), route, dosing frequency, and the representative clinical scenario for each.

☐ Chart 4 — Inhaled vs. Systemic Corticosteroids: Indication (controller vs. exacerbation), dosing (daily vs. burst), side-effect profile (local vs. systemic), preventable side effects (rinse and spit; spacer use), and the threshold that signals chronic systemic exposure.

Cornell Notes:

☐ Page 1 — Cue questions: What is the absolute prohibition on LABA use in asthma, and how does SMART therapy use ICS-formoterol to satisfy both controller and reliever roles? What does SABA overuse signal, and what is the wrong answer the exam builds around it?

☐ Page 2 — Cue questions: What is the LTRA boxed warning, and what is the appropriate response when a patient on montelukast develops new neuropsychiatric symptoms? What are the typical durations of a systemic corticosteroid burst in adults versus children, and at what frequency does repeated bursting itself become a step-up trigger?

☐ Page 3 — Cue questions: What is the target and selecting biomarker for each of the 

six biologics — omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab? Which biologic is the right choice for a Type-2 high patient with co-existing atopic dermatitis or nasal polyps, and which is the right choice when the eosinophil count is low?

Week 6 — Part VI: Management — Devices and Technique

Difficulty: Heavy — High Yield

What it covers: Part VI is the most directly tested skill domain on the AE-C — the device the medication is delivered through and the technique the patient uses. You will learn the four major delivery devices (pMDI, DPI, soft-mist inhaler, nebulizer) by mechanism, technique, and patient fit, common MDI errors at each step, DPI inspiratory flow requirements and which patients can't generate them, mask versus mouthpiece spacer interfaces, MDI priming rules, structured return demonstrations with criteria-based evaluation, the inhaler-versus-nebulizer decision based on the clinical situation rather than default, and cleaning and replacement schedules for every component.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the MDI versus DPI inhalation rule before anything else in this Part. A pressurized metered-dose inhaler (pMDI) requires a SLOW and DEEP inhalation (about 30 L/min) over 3–5 seconds, followed by a 10-second breath hold — the slow draw allows the propellant cloud to settle into the lower airways. A dry powder inhaler (DPI) requires a FAST and FORCEFUL inhalation (typically at least 60 L/min) — the patient's own inspiratory flow is what disperses the powder into respirable particles. The two techniques are OPPOSITE, and the AE-C tests this by varying which device is in the stem. Coaching a DPI like an MDI (or vice versa) is the most common technique error in patients who switch devices.

☐ Master the spacer/VHC rule. A spacer is an open tube placed between an MDI and the patient that allows the propellant to slow before inhalation, reducing the coordination demand. A valved holding chamber (VHC) is a spacer with a one-way valve that holds the aerosol cloud until inhalation begins — preferred over a simple spacer because it tolerates poor coordination. Spacers and VHCs are recommended for ALL pMDI users (especially children and the elderly) and are REQUIRED for inhaled corticosteroid pMDI users to reduce oropharyngeal deposition and oral thrush. After ICS use, the patient rinses, gargles, and spits to further reduce thrush risk.

☐ Build a clean reference for mask versus mouthpiece interface selection. A mouthpiece is preferred whenever the patient is able to seal their lips on it — it delivers more medication to the lower airways and less to the face. A mask is used in young children (typically under 4 years), patients who cannot seal their lips, and patients with cognitive limitations. The mask must form a tight seal against the face — gaps of even a few millimeters dramatically reduce delivered dose. The transition from mask to mouthpiece is a milestone in pediatric asthma education and is reassessed at every visit.

☐ Anchor MDI priming. Priming is releasing test sprays before first use — or after a period of non-use — to ensure the next actuation contains a full dose. Specific instructions vary by product, but the principle is universal: a brand-new canister or one that has sat unused needs priming sprays (typically 1–4 sprays into the air, away from the face) before the first patient dose. Failing to prime delivers a partial dose without the patient knowing — and leads to "the inhaler isn't working" complaints with normal devices.

☐ Master the nebulizer-versus-inhaler decision. A nebulizer is NOT inherently better than a pMDI with spacer — for stable asthma in patients with adequate technique, the inhaler delivers equivalent medication to the lungs in a fraction of the time and with a fraction of the cost. The nebulizer is selected when the patient cannot perform inhaler technique adequately (severe exacerbation with exhaustion, very young children unable to coordinate even with mask, severe cognitive limitation), when continuous delivery is needed (severe ED exacerbations), or when specific medications are only available as a nebulizer solution. The exam tests the bias toward "more medication = nebulizer" as the wrong answer.

☐ Master the structured return demonstration. A return demonstration is the patient performing the device technique while the educator observes against a checklist — every step scored, every error coached. This is the ONLY way to confirm technique, because patients consistently overestimate their own technique on self-report. The AE-C tests the return demonstration as the gold-standard technique-assessment method and as the routine practice at every follow-up visit, not just at initiation.

☐ Complete the Practice Questions for Part VI in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Devices and Technique. Main branches: pMDI (slow, deep, breath hold, prime) → DPI (fast, forceful, no spacer, moisture sensitivity) → Soft-Mist Inhaler → Nebulizer (indications, infection control) → Spacer & VHC → Mask vs. Mouthpiece Interface → Peak Inspiratory Flow & Device Fit → MDI Priming Rules → Cleaning & Replacement Schedules → Static Charge → Dose Counter → Return Demonstration → Inhaler-vs.-Nebulizer Decision.

Comparison Charts:

☐ Chart 1 — pMDI vs. DPI vs. SMI vs. Nebulizer: Inhalation type required (slow vs. fast vs. slow-mist vs. tidal), coordination demand, inspiratory flow requirement, propellant present (yes/no), age and capacity that fit each, and the most common technique error for each.

☐ Chart 2 — Spacer vs. Valved Holding Chamber vs. No Spacer: One-way valve present (yes/no), tolerance for poor coordination, indication (all pMDI users vs. ICS pMDI required), pediatric fit, and the cleaning rule that prevents static charge.

☐ Chart 3 — Mouthpiece vs. Mask Interface: Patient capacity (lip seal, age, cognitive ability), delivered dose to lower airways, hygiene considerations, transition timing in pediatrics, and the seal-quality check the educator performs.

☐ Chart 4 — Inhaler with Spacer vs. Nebulizer: Time per dose, cost per dose, equivalence in stable asthma (yes), indication for nebulizer (severe exacerbation, exhaustion, very young child, continuous delivery), and the exam-stem trap built around "more medication = nebulizer."

Cornell Notes:

☐ Page 1 — Cue questions: What is the inhalation technique for a pMDI versus a DPI, and why are the two opposite? What is the breath-hold time after pMDI inhalation, and what does it accomplish?

☐ Page 2 — Cue questions: What is the difference between a spacer and a valved holding chamber, and which patients absolutely require one with their pMDI? What is the rinse-and-spit rule after ICS use, and which side effect does it prevent?

☐ Page 3 — Cue questions: What is the structured return demonstration, and why is patient self-report not sufficient to confirm technique? What three clinical situations select a nebulizer over a pMDI with spacer, and which exam-stem framing produces the wrong answer?

Week 7 — Part VII: Management — Triggers and Behavioral Modifications

Difficulty: Moderate–Heavy

What it covers: Part VII is the environmental and behavioral counseling Part — the everyday changes that reduce trigger exposure and shift asthma trajectory. You will learn why multifaceted environmental interventions outperform any single step, dust mite mitigation (encasings, hot-water washing, humidity below 50%, flooring choices), the realities of pet dander persistence, secondhand and thirdhand smoke and e-cigarette/vape exposure, the indications for HEPA filtration and allergen-impermeable encasings, the 5 A's tobacco cessation framework (Ask, Advise, Assess, Assist, Arrange), evidence-based prevention of exercise-induced bronchoconstriction (EIB), asthma management in pregnancy, and culturally competent counseling so recommendations are realistic, respectful, and adoptable.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the multifaceted-intervention rule before anything else in this Part. A multifaceted intervention is a combined package of environmental control measures (encasings, cleaning, humidity control, HEPA filtration) — the evidence shows multifaceted approaches outperform ANY single step in reducing exposure and improving control. The exam tests this by giving a stem where the wrong answer is "just use HEPA" or "just use encasings" — the right answer is the combination.

☐ Master dust mite mitigation. The dust mite is a microscopic mite that thrives in warm, humid bedding and upholstery — a major perennial indoor allergen. Mitigation requires allergen-impermeable encasings on mattresses, pillows, and box springs; weekly washing of bedding in hot water (130°F / 54.4°C or higher) to kill mites; indoor humidity kept below 50% to suppress mite proliferation; reduction of carpeting where feasible; and frequent vacuuming with a HEPA filter. Any one of these alone is insufficient; the package matters.

☐ Build a clean reference for tobacco and the 5 A's. Secondhand smoke is inhalation of smoke produced by burning tobacco products or exhaled by a smoker — a significant trigger and a strong long-term risk factor for asthma onset and severity. Thirdhand smoke is residual nicotine and chemicals deposited on surfaces, clothing, and dust after smoking — re-aerosolized and particularly relevant for infants and young children. E-cigarettes and vape products are NOT a safe alternative for asthma patients. The 5 A's framework — Ask, Advise, Assess, Assist, Arrange follow-up — is the structured tobacco-cessation pattern endorsed by the U.S. Public Health Service. Nicotine replacement therapy (patches, gum, lozenges, inhalers, nasal spray) is first-line pharmacotherapy combined with behavioral support.

☐ Anchor exercise-induced bronchoconstriction (EIB). EIB is transient airway narrowing during or shortly after exercise, peaking 5–15 minutes post-exercise. It occurs in patients with baseline asthma AND in athletes without baseline asthma. Pre-exercise SABA (inhaled albuterol given 15 minutes before exercise) is effective at preventing EIB but should be re-evaluated when used regularly — frequent use can mask poor underlying control. Warm-up exercise produces a refractory period (1–3 hours) during which subsequent exercise produces less bronchoconstriction, and is the basis for warm-up as prevention. The wrong answer on the exam is "stop exercising" — the right answer is to enable exercise with appropriate prevention.

☐ Master asthma in pregnancy. The Pregnancy Rule of Thirds: roughly one-third of pregnant patients experience worsening, one-third improve, and one-third have no change — predicting which group an individual falls into is unreliable. The principle is to maintain control rather than reflexively discontinue medications. Budesonide is the inhaled corticosteroid with the most accumulated safety data in pregnancy and is the preferred ICS for newly initiated therapy in pregnant patients; patients already controlled on a different ICS are typically continued on it rather than switched. Uncontrolled asthma is more dangerous to mother and fetus than the medications used to control it.

☐ Complete the Practice Questions for Part VII in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Triggers and Behavioral Modifications. Main branches: Multifaceted Intervention Principle → Dust Mite Mitigation (encasings, hot wash, humidity, flooring) → Pet Dander → Cockroach & Mouse → Mold & Pollen → Secondhand & Thirdhand Smoke → E-Cigarette/Vape → HEPA Filtration & Allergen-Impermeable Encasings → 5 A's Tobacco Cessation → Nicotine Replacement Therapy → Exercise-Induced Bronchoconstriction (EIB) → Pre-Exercise SABA → Warm-Up Refractory Period → Asthma in Pregnancy (Rule of Thirds, Budesonide) → Cultural Competence in Trigger Counseling.

Comparison Charts:

☐ Chart 1 — Single-Step vs. Multifaceted Environmental Intervention: Effectiveness, evidence base, examples of single-step traps the exam uses, and why combinations work where individual steps fail.

☐ Chart 2 — Secondhand Smoke vs. Thirdhand Smoke vs. E-Cigarette/Vape Aerosol: Source, persistence in the home environment, populations most affected (especially infants for thirdhand), counseling priority, and the misconception each one creates for patients.

☐ Chart 3 — EIB Prevention Strategies: Pre-exercise SABA, warm-up refractory period, ICS controller for underlying inflammation, environmental modification (avoid cold-dry air exposure), and the exam-stem framing that points to each.

Cornell Notes:

☐ Page 1 — Cue questions: Why does a multifaceted environmental intervention outperform any single step, and what is the most common single-step trap on the exam? What are the components of comprehensive dust mite mitigation, and what wash temperature kills mites in bedding?

☐ Page 2 — Cue questions: What are the five steps of the 5 A's tobacco cessation framework, and what role does nicotine replacement therapy play? What is the Pregnancy Rule of Thirds, and which inhaled corticosteroid has the most accumulated safety data for newly initiated therapy in pregnancy?

Week 8 — Part VIII: Management — Action Plans and Self-Management

Difficulty: Heavy — High Yield

What it covers: Part VIII is where the entire book becomes a one-page document the patient can act on — the written asthma action plan. You will learn the green/yellow/red zone system, how to tailor an action plan to age, severity, comprehension, and life context, how to establish a personal best peak flow over a 2- to 3-week period of well-controlled asthma, how to calculate green (≥80% of personal best), yellow (50–79%), and red (<50%) zone thresholds, common peak flow technique errors and how to coach them, the integration of action plans into school (Section 504, self-carry inhaler laws) and workplace (ADA accommodations) settings, individualizing self-management for life context, and building patient decision-making for early warning signs and escalation.

Print: 1 Mind Map, 4 Comparison Charts, 3 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the green/yellow/red zone thresholds before anything else in this Part. Green zone (the "doing well" zone): peak flow at least 80% of personal best AND no asthma symptoms — the patient continues daily controller therapy as prescribed. Yellow zone (the "caution" zone): peak flow 50–79% of personal best, OR mild symptoms (cough, wheeze, tight chest, nighttime awakening) — the patient adds reliever therapy per the plan and may add a short-term controller increase. Red zone (the "medical alert" zone): peak flow less than 50% of personal best, severe symptoms, or no improvement with reliever therapy — emergency action is required, including urgent reliever, oral steroid burst per the plan, and a call to the provider or 911. The thresholds and the action are tested as a paired set.

☐ Master the personal best peak flow protocol. The personal best is established over a 2- to 3-week period of well-controlled asthma — the patient measures peak flow twice daily (morning and evening, before reliever use if possible), records each best-of-three value, and the highest reliable reading becomes the personal best. The personal best, NOT predicted values, is the reference for action plan zones because predicted values miss patient-specific variation. Personal best is recalculated whenever a clinically meaningful change occurs (new controller, growth in pediatrics, sustained step-down).

☐ Build a clean reference for symptom-based vs. peak-flow-based action plans. Symptom-based action plans trigger zone changes on symptoms rather than peak flow values — preferred for young children, patients who don't use peak flow, and those who perceive symptoms reliably. Peak-flow-based plans use peak flow values to define zone transitions, often combined with symptom criteria — useful for poor symptom perceivers and those comfortable with daily monitoring. Many plans use BOTH and trigger on whichever crosses first. The choice is patient-specific, not categorical.

☐ Anchor the school and workplace integration rules. A school action plan is a copy of the asthma action plan provided to the school nurse, teacher, and coach with emergency contacts and self-carry medication permissions documented. A Section 504 plan is a U.S. legal accommodation in public schools that provides equal access for students with health conditions including asthma. ADA accommodations are workplace adjustments under the Americans with Disabilities Act that may include trigger avoidance, schedule flexibility, and access to rescue medication. Self-carry inhaler laws are state-level laws permitting students to carry and self-administer rescue inhalers under specific provisions — coverage varies, so check the patient's state. Distributing the action plan to every setting where care is delivered is the routine standard, not an exceptional step.

☐ Master peak flow technique. Three forced exhalations are taken, the highest is recorded, and technique errors include incomplete inhalation before the maneuver, leak around the mouthpiece, tongue blocking the device, and not standing up straight. The exam tests technique correction by giving a stem where the patient's PEF is much lower than expected and asking what to check first — technique, not the underlying disease.

☐ Complete the Practice Questions for Part VIII in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Action Plans and Self-Management. Main branches: Green Zone (≥80%, no symptoms) → Yellow Zone (50–79%, mild symptoms) → Red Zone (<50%, severe symptoms) → Personal Best Peak Flow → Predicted vs. Personal Best → Peak Flow Technique → Symptom-Based vs. Peak-Flow-Based Plan → School Action Plan → Section 504 → Self-Carry Inhaler Laws → ADA Workplace Accommodations → Early Warning Signs → Decision-Making Skill → Reassessment Window → Plan Distribution.

Comparison Charts:

☐ Chart 1 — Green vs. Yellow vs. Red Zone: Peak flow threshold (% of personal best), characteristic symptoms, action (continue, add reliever, emergency), and the most common patient-side decision error in each zone.

☐ Chart 2 — Personal Best vs. Predicted Peak Flow: How each is determined, sources of variation, accuracy for individual patients, when to recalculate, and the reason action plans should use personal best rather than predicted.

☐ Chart 3 — Symptom-Based vs. Peak-Flow-Based Action Plan: Triggering criteria, populations preferred (young children, poor perceivers, daily monitors), patient capacity demands, and the hybrid approach that uses whichever crosses first.

☐ Chart 4 — School-Setting Integration: School Action Plan vs. Section 504 vs. Self-Carry Inhaler Laws — what each is, who maintains it, what it provides legally, and how each fits into the patient's overall plan.

Cornell Notes:

☐ Page 1 — Cue questions: What are the green, yellow, and red zone peak flow thresholds (as % of personal best), and what action does each zone trigger? Why is personal best, not predicted, the reference for action plan zones?

☐ Page 2 — Cue questions: What is the protocol for establishing a personal best peak flow over a 2- to 3-week period? When is a symptom-based action plan preferred over a peak-flow-based plan, and which patients fall into each category?

☐ Page 3 — Cue questions: What is a Section 504 plan, and how does it differ from a school action plan and from self-carry inhaler laws? What ADA accommodations may apply to an asthma patient in the workplace, and how does the AE-C educate the patient to request them?

Week 9 — Part IX: Reevaluation and Follow-Up

Difficulty: Moderate

What it covers: Part IX moves the encounter from initiation to maintenance — the structured follow-up that keeps control durable. You will learn how to reassess control at every visit using a framework that spans symptoms, exacerbations, medications, technique, and triggers, the validated control instruments (ACT for ages 12+, C-ACT for ages 4–11, ACQ, TRACK for under-5), how to revise action plans after a personal best change, how to reassess adherence using refill history plus conversational probing plus inhaler-technique observation, the triggers that prompt action plan revision, the criteria for stepping up versus stepping down therapy, and how to document follow-up in a way that supports continuity across the care team.

Print: 1 Mind Map, 3 Comparison Charts, 2 Cornell Notes pages

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in the validated control instruments by age before anything else in this Part. Asthma Control Test (ACT) is for ages 12 and older — five questions, scores 5–25, with a score of 20 or higher indicating well-controlled asthma. Childhood Asthma Control Test (C-ACT) is for ages 4–11 and combines child-reported and parent-reported items — total scores of 19 or less suggest poorly controlled asthma. Asthma Control Questionnaire (ACQ) is a 5- to 7-item instrument scored 0–6: mean scores of 1.5 or greater indicate uncontrolled asthma, and 0.75–1.5 indicates partly controlled status. TRACK (Test for Respiratory and Asthma Control in Kids) is a parent-completed tool for children under 5 where the standard ACT is not validated. Matching the instrument to the patient's age is the most directly tested skill in this Part.

☐ Master the step-up vs. step-down rule. Step-up is escalation of controller therapy after confirmed adherence, technique, trigger control, and comorbidity audits when control is inadequate — NOT the first-line response to "still symptomatic" if the audits haven't been done. Step-down is reduction of controller therapy after AT LEAST 3 MONTHS of stable, well-controlled asthma, aimed at maintaining control on the lowest effective regimen. Stepping down too early is a common cause of recurrent loss of control, and stepping up before auditing is a common cause of unnecessary therapy escalation.

☐ Build a clean reference for adherence reassessment. Adherence is reassessed at every visit using THREE complementary methods: (1) refill history — the objective record of pharmacy fills; gaps signal under-use; (2) conversational probing — open-ended questions about how the patient is using the controller in real life ("Some patients find it hard to use a daily inhaler when they feel fine — how is that going for you?"); (3) inhaler technique observation — a return demonstration that confirms the dose actually reaches the lungs. Patient self-report alone consistently overestimates adherence; the AE-C exam tests the use of the multi-method approach.

☐ Anchor the post-exacerbation follow-up window. A post-exacerbation visit is a short-interval follow-up scheduled within 1–4 weeks after any exacerbation requiring oral corticosteroids, ED care, or hospitalization. The visit covers what triggered the event, what the patient did and what changed in their environment, whether the action plan worked or needs revision, controller adjustment, technique re-check, and trigger reassessment. The exam tests this as a non-negotiable standard, not a courtesy.

☐ Master the action plan revision triggers. The plan is revised whenever (1) personal best peak flow changes substantially (growth in pediatrics, sustained step-down, recovery from a long bad period); (2) the controller regimen changes; (3) emergency contacts or pharmacy information change; (4) life circumstances change (school transition, occupation change, pregnancy); (5) post-exacerbation lessons reveal a gap. A plan that hasn't been revised in over a year is itself a red flag.

☐ Complete the Practice Questions for Part IX in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Reevaluation and Follow-Up. Main branches: Reassessment Framework (symptoms, exacerbations, meds, technique, triggers, comorbidities) → Validated Control Instruments (ACT, C-ACT, ACQ, TRACK) → Personal Best Recalculation → Action Plan Revision Triggers → Adherence Reassessment (refill history, conversational probing, technique observation) → Step-Up Criteria & Pre-Audit → Step-Down Criteria (≥3 months stable) → Post-Exacerbation Visit Window → Annual Review → Care Team Communication.

Comparison Charts:

☐ Chart 1 — Validated Control Instruments by Age: ACT vs. C-ACT vs. ACQ vs. TRACK — age range, items, scoring, threshold for control vs. uncontrolled, and the population each is preferred for.

☐ Chart 2 — Step-Up vs. Step-Down Decision: When considered, prerequisite audits (adherence, technique, triggers, comorbidities), timing requirement, monitoring after the change, and the failure mode each side produces if applied without the prerequisite.

☐ Chart 3 — Adherence Reassessment Methods: Refill history vs. conversational probing vs. inhaler technique observation — what each captures, what each misses, why all three are needed, and the wrong-answer trap of relying on patient self-report alone.

Cornell Notes:

☐ Page 1 — Cue questions: What are the four validated asthma control instruments, what age ranges are they validated for, and what score threshold indicates well-controlled vs. uncontrolled asthma in each? When is a personal best peak flow recalculated, and why?

☐ Page 2 — Cue questions: What audits must be completed BEFORE stepping up controller therapy, and what is the minimum duration of stable control required before stepping down? What is the post-exacerbation follow-up window, and what does the visit cover?

Week 10 — Part X: Organizational Issues

Difficulty: Light–Moderate

What it covers: Part X closes the book by zooming out from the individual patient to the program — the organizational and regulatory framework that supports asthma education at scale. You will learn the components of a comprehensive needs assessment, program development prioritization with logic models and SMART goals, the distinct scope of HIPAA, FERPA, and OSHA, the four program evaluation domains (process, impact, outcome, economic), the RE-AIM framework, validated evaluation tools (ACT, C-ACT, AQLQ/PAQLQ, TRACK), how to assess health literacy at the program level (REALM, TOFHLA, Newest Vital Sign), the CRAFT critique framework (Credibility, Readability, Accuracy, Freshness, Targeted audience fit) for educational materials, partnership building with payers, schools, worksites, faith-based and community organizations, and patient assistance programs (NeedyMeds, RxAssist, manufacturer programs).

Print: 1 Mind Map, 2 Comparison Charts, 1 Cornell Notes page

Study Tasks

☐ Read the Study Guide first — complete the High-Yield Objectives, Key Terms and Definitions, and Concept Overview sections before opening the chapter.

☐ Highlight as you read — follow the Made Easy Highlighting System 

☐ Lock in HIPAA vs. FERPA vs. OSHA before anything else in this Part. HIPAA is the federal law setting standards for privacy and security of Protected Health Information — applies to covered entities (clinics, hospitals, plans) and is enforced by the HHS Office for Civil Rights. FERPA is the federal law governing student education records, including health information held by schools — enforced by the U.S. Department of Education. The same patient-asthma fact may be HIPAA-protected at the clinic and FERPA-protected at the school. OSHA is the federal agency that sets and enforces workplace safety standards, including respiratory hazards and occupational asthma. The exam tests this by giving a scenario and asking which law applies — the setting (clinic, school, workplace) is the testable signal.

☐ Master the four evaluation domains. Process evaluation answers "Did we do what we planned?" — reach, dose, fidelity, adoption. Impact evaluation answers "Did the program produce the changes we expected in participants?" — knowledge, attitudes, self-efficacy, behaviors. Outcome evaluation answers "Did clinical and quality-of-life outcomes improve?" — asthma control, exacerbations, ED visits, hospitalizations, missed school/work, quality of life. Economic evaluation is cost-tied analysis — cost-effectiveness, cost-benefit, return-on-investment. The exam matches a question to the right evaluation level.

☐ Build a clean reference for the RE-AIM framework. RE-AIM is Reach, Effectiveness, Adoption, Implementation, Maintenance — used to plan and assess public health programs. Reach is who the program serves; Effectiveness is whether outcomes improve; Adoption is whether settings and providers take up the program; Implementation is whether it is delivered as designed; Maintenance is whether the program persists over time. Each letter is its own testable concept.

☐ Anchor the CRAFT material critique. CRAFT is the framework for evaluating educational materials by Credibility (source authority), Readability (target reading level — 5th to 8th grade for general health materials, with SMOG and Flesch-Kincaid as common scores), Accuracy (current evidence), Freshness (date of last update), and Targeted audience fit (cultural and language fit). A material that scores well on credibility but at a 12th-grade reading level fails — the bar is the WEAKEST element, not the average.

☐ Master patient assistance programs. A patient assistance program is manufacturer- or nonprofit-sponsored, providing reduced-cost or free medications for eligible patients. NeedyMeds is a clearinghouse that aggregates programs across drugs and conditions; RxAssist is a similar aggregator; individual manufacturers run program-specific assistance for branded therapies (especially biologics). Knowing where to send a patient struggling with cost is a routine AE-C skill, not an unusual escalation.

☐ Complete the Practice Questions for Part X in your quiz bank. Review every rationale — correct and incorrect.

How to Use Your Templates

Mind Map: Central node = Organizational Issues. Main branches: Needs Assessment → Logic Model → SMART Goals → HIPAA → FERPA → OSHA → Process / Impact / Outcome / Economic Evaluation → RE-AIM Framework → Validated Tools (ACT, C-ACT, AQLQ/PAQLQ, TRACK) → Health Literacy Assessment (REALM, TOFHLA, Newest Vital Sign) → Readability Scores (SMOG, Flesch-Kincaid) → CRAFT Critique → Community & Faith-Based Partnerships → Community Health Worker → Patient Assistance Programs.

Comparison Charts:

☐ Chart 1 — HIPAA vs. FERPA vs. OSHA: What each protects, the setting where it applies (clinic vs. school vs. workplace), the enforcing agency, common scenarios on the exam, and the asthma educator's compliance obligation under each.

☐ Chart 2 — Process vs. Impact vs. Outcome vs. Economic Evaluation: The question each one answers, example metrics, the program-development phase each is matched to, and the wrong-answer trap of conflating impact (knowledge change) with outcome (clinical change).

Cornell Notes:

☐ Page 1 — Cue questions: What is the difference between HIPAA, FERPA, and OSHA in scope, setting, and enforcement, and which one applies to an asthma fact held by a school nurse versus a workplace? What are the four program evaluation domains, and what question does each one answer? What are the five elements of the RE-AIM framework, and what is the recommended reading level for general health education materials?

Week 11 — Full Review & Exam Simulation

Your final week is not about learning new material — it is about consolidating everything you have built and proving it under exam conditions.

Review Tasks

☐ Re-draw one Mind Map from memory for each Part you feel least confident about. Check it against your original.

☐ Work through your Cornell Notes cue columns for every Part — cover the right-hand notes and answer from memory.

☐ Re-do any quiz bank questions you got wrong across all Parts. Focus on the rationales.

☐ Review the Common Mistakes, Rapid Review, and Self-Assessment Checklist sections for your two or three weakest Parts.

Exam Simulation

☐ Take the full-length AE-C practice exam using the QR code in the back matter of this book. Complete it in one sitting, timed, as close to real exam conditions as possible.

☐ Review your emailed score report. Identify which Parts you missed most and spend your remaining time on those Parts' Rapid Review and clinical scenarios only.